BGG492

Phase 2Small molecule

Novartis

BGG492 is one of 119 small molecule programs targeting Partial Epilepsy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

Partial EpilepsyActive, not recruiting

Photosensitive EpilepsyActive, not recruiting

SeizureActive, not recruiting

Multiple SclerosisActive, not recruiting

MigraineActive, not recruiting

Partial EpilepsyPhase 2

Active, not recruiting

Photosensitive EpilepsyPhase 2

Active, not recruiting

SeizurePhase 2

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

MigrainePhase 2

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

BGG492

Novartis

Phase 2

1 2

Betaseron

Bayer

Preclinical

16 3

Kesimpta

Novartis

Preclinical

15 4

Tysabri

Biogen

Preclinical

14 5

Campath

GGenzyme, a Sanofi Company

Preclinical

12 6

Zinbryta

Roche

Preclinical

2 7

Flomax

Sanofi

Preclinical

1 8

Novantrone

Pred Forte

Myfortic

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Migraine2 trials

A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention

Withdrawn· Novartis logo

Novartis·Phase 2·NCT01617941

Efficacy and Safety of BGG492 in the Treatment of Migraine

Completed· Novartis logo

Novartis·Phase 2·NCT00892203·75 enrolled

Seizure1 trial

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

Withdrawn· Novartis logo

Novartis·Phase 2·NCT01167335

Partial Epilepsy1 trial

Phase II BGG492 Capsule Extension for Partial Epilepsy

Completed· Novartis logo

Novartis·Phase 2·NCT01338805·56 enrolled

Multiple Sclerosis1 trial

Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis

Withdrawn· Novartis logo

Novartis·Phase 2·NCT01649050

Photosensitive Epilepsy1 trial

Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

Completed· Novartis logo

Novartis·Phase 2·NCT00784212·13 enrolled

1 more indication

Unspecified1 trial

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Completed· Novartis logo

Novartis·Phase 2·NCT02150213·59 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for BGG492. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGG492 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGG492. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

BGG492

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Migraine2 trials

Seizure1 trial

Partial Epilepsy1 trial

Multiple Sclerosis1 trial

Photosensitive Epilepsy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News